Therefore, encouraged by the results obtained on the rat and mouse models, we performed proof-of-concept studies in a mouse model for triple negative breast cancer to demonstrate the therapeutic potential of targeting gC1qR with an antibody directed against the C1q binding site of gC1qR (Figure 6). Here, C1QBP is linked to triple-negative breast carcinoma.